"Nature": The top ten forecasts of global drug sales in 2022

Top 20 best-selling drugs in the world as of 2021.
9

In 2021, in "Nature"'s global drug sales forecast for that year, it ignored the consideration of the drug approval process caused by COVID-19
.

Because the two best-selling drugs, the COVID-19 vaccine Comirnaty (tozinameran; Pfizer/BioNTech) and Spikevax (Moderna), both received emergency use authorization (EUA) in December 2020
.

These two vaccines will still occupy an important position in 2022.
Some financial analysts predict that Pfizer/BioNtech and Moderna’s vaccine sales will continue to increase due to their use in lower age groups, the potential demand for the fourth dose, and Increase in production capacity
.

And recently, due to the influence of Omi Keron, the wave of vaccination among people around the world has continued, but it is estimated that the duration will not be too long

Estimated global drug sales in 2022

Adalimumab, theglobal drug king, will rank second in the drug sales ranking in 2022
.

Among the TOP100 varieties of global drug sales in 2020, the first place is still adalimumab , which has remained unchanged for thousands of years .

Adalimumab Adalimumab

Since 2012, Adalimumab has consistently ranked first in global prescription drug sales, and has been the veritable "drug king" for nearly ten consecutive years
.

Although Humira may no longer occupy the top-selling position, it is still one of the best-selling drugs in pharmaceutical history

Figure 1.
Blockbuster drugs about to experience the patent cliff

The rise in the ranking of Keytruda (pembrolizumab) is also affected by the COVID-19 vaccine
.

Merck & Co.

Keytruda (pembrolizumab) Keytruda is expected to surpass Humira to top the list in 2024

Currently, checkpoint inhibitors continue to rapidly expand to new indications and treatment lines
.

Keytruda is currently used in nearly 40 indications, and the most recently approved as an adjuvant therapy for renal cell carcinoma should help Keytruda achieve its $19.

Over time, K medicine will only further expand the gap between it and its competitor Opdivo (nivolumab)
.

It is estimated that by 2022, Bristol Myers Squibb's anti-PD1 mAb sales will account for less than half of Keytruda's sales

Opdivo (nivolumab)

On the surface, Bristol-Myers Squibb seems to be doing well, and there are two other drugs in the top 10
.

However, Revlimid (lenalidomide) is facing imminent competition, and four generic drug companies have now been approved for sales after March 2022

Revlimid (lenalidomide)

Competition on the autoimmune disease track is also fierce, especially the sales of anti- IL-12/IL-23 mAb (Stelara (ustekinumab)) exceeding 9 billion U.
S.
dollars make it an attractive target
.

Currently, many biosimilar companies are waiting for their patents to expire in 2023.

IL-12/IL-23 mAb (Stelara (ustekinumab))

In contrast, Biktarvy (bictegravir, emtricitabine and tenofovir) and Dupixent (dupilumab) should remain in the top 10 in the next few years, thanks to their long-term patents and strong sales potential
.
It is expected that Biktarvy will continue to dominate HIV treatment with its daily oral triple combination therapy, while the atopic dermatitis drug Dupixent is expected to surpass Biktarvy and become the second most sold product in 2026, second only to Keytruda
.

Biktarvy (bictegravir, emtricitabine and tenofovir) and Dupixent (dupilumab)

However, the new crown pandemic also tells us that some drugs can become blockbusters in just one year, such as the COVID-19 oral antiviral drugs developed by Merck/ Ridgeback and Pfizer
.
Merck has announced that it has signed a $2.
2 billion Lagevrio (molnupiravir) contract with the U.
S.
government, and Pfizer has also signed a similar $5.
29 billion contract for the purchase of the new drug Paxlovid (PF-07321332 and Lee Tonavir)
.
Therefore, these two drugs may also reach the top ten global drug sales in 2022
.

Ridgeback Merck has announced that it has signed a $2.
2 billion Lagevrio (molnupiravir) contract with the U.
S.
government, and Pfizer has also signed a similar $5.
29 billion contract for the purchase of the new drug Paxlovid (PF-07321332 and PF-07321332).
Ritonavir)

references:

references:

1.
Top product forecasts for 2022 (nature.
com)

1.
Top product forecasts for 2022 (nature.
com)

2.
https://